March 14, 2024Open Access

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients

Key Points

Key points are not available for this paper at this time.

Abstract

The ORAL Surveillance trial found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Charles‐Schoeman et al. (Thu,) studied this question.

synapsesocial.com/papers/68e73fdcb6db6435876b9615 https://doi.org/https://doi.org/10.1002/art.42846

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper